6 completed, 2 not yet recruiting, 1 active not recruiting, 1 withdrawn. 7 Phase 1, 3 Phase 2, 1 Phase 3.
By phase and status
Follow Xentria, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
An Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations
XTMAB-16, Placebo - Pulmonary Sarcoidosis | Phase 2 | Not yet recruiting | Xentria, Inc. | 182 | 2026-10-30 | 2026-10-21 |
A Study to Investigate the Pharmacokinetics and Safety of KM04 Compared to United States (US)-Gonal-f Revised Formulation Female (RFF) Redi-ject and European Union (EU)-Gonal-f in Healthy Adult Female Volunteers
KM04, Unites States (US)-Gonal-f® Revised Formulation Female (RFF) Redi-ject®, European Union (EU)-Gonal-f® - Healthy Female Adult Volunteers | Phase 1 | Not yet recruiting | Xentria, Inc. | 42 | 2026-10-01 | 2026-08-31 |
Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(L), US-Humalog®, and EU-Humalog®
NKF-INS(L), US-Humalog®, EU-Humalog® - Healthy Male Adult Volunteers | Phase 1 | Completed | Xentria, Inc. | 54 | 2025-10-13 | 2026-03-06 |
Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®
MAB-22, Prolia® - Osteoporosis | Phase 3 | Withdrawn | Xentria, Inc. | | 2025-10-01 | 2025-05-11 |
Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus®
NKF-INS(G), US-Lantus®, EU-Lantus® - Healthy Participants | Phase 1 | Completed | Xentria, Inc. | 114 | 2024-10-29 | 2026-10-23 |
Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(A), US-NovoLog®, and EU-NovoRapid®
NKF-INS(A), EU-NovoRapid®, US-NovoLog® - Healthy Participants | Phase 1 | Completed | Xentria, Inc. | 54 | 2024-07-30 | 2026-01-21 |
Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®
MAB-22, EU-Prolia®, US-Prolia® - Healthy Participants | Phase 1 | Completed | Xentria, Inc. | 225 | 2024-06-05 | 2025-07-29 |
An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
XTMAB-16 - Pulmonary Sarcoidosis | Phase 2 | Completed | Xentria, Inc. | 31 | 2024-03-01 | 2026-10-16 |
Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations
XTMAB-16 or Placebo - Pulmonary Sarcoidosis | Phase 1 / Phase 2 | Active not recruiting | Xentria, Inc. | 32 | 2023-11-10 | 2026-10-02 |
Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Infusion of XTMAB-16 in Healthy Adult Participants
Placebo, XTMAB-16 2 mg/kg, XTMAB-16 4mg/kg - Healthy Participants | Phase 1 | Completed | Xentria, Inc. | 25 | 2021-06-25 | 2025-01-14 |
Conditions studied
Sarcoidosis, Pulmonary (3) · Osteoporosis (1)
Interventions
Denosumab (1)
Countries
South Africa (3) · United States (3) · Czechia (2) · Poland (2) · United Kingdom (2) · Denmark (1) · Hungary (1) · Netherlands (1) · Spain (1)
Top investigators
Ray Goldwater, MDCM, M.Sc(A), CPI (1)